Cubicin’s High Rate Of Persisting/Relapsing Bacteremia To Be Discussed By Committee

FDA’s Anti-Infective Drugs Advisory Committee will also provide advice on study designs for patients with infective endocarditis during its March 6 review of Cubist’s daptomycin.